Centessa Pharmaceuticals Financials
CNTA Stock | USD 14.54 1.27 8.03% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 11.65 | 9.2487 |
|
|
Investors should never underestimate Centessa Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Centessa Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Centessa Pharmaceuticals PLC.
Net Income |
|
Centessa | Select Account or Indicator |
Understanding current and past Centessa Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Centessa Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Centessa Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Centessa Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Centessa Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Centessa Pharmaceuticals' management manipulating its earnings.
Centessa Pharmaceuticals Stock Summary
Centessa Pharmaceuticals competes with Century Therapeutics, Edgewise Therapeutics, C4 Therapeutics, Mineralys Therapeutics,, and Cullinan Oncology. Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom. Centessa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 68 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US1523091007 |
CUSIP | 152309100 |
Location | United Kingdom |
Business Address | 1 Ashley Road, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.centessa.com |
Phone | 44 203 9206789 |
Currency | USD - US Dollar |
Centessa Pharmaceuticals Key Financial Ratios
Return On Equity | -0.43 | ||||
Operating Margin | (23.59) % | ||||
Price To Sales | 323.19 X | ||||
Gross Profit | 6.85 M | ||||
EBITDA | (201.06 M) |
Centessa Pharmaceuticals Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 11.7M | 629.6M | 444.3M | 360.2M | 576.8M | 374.4M | |
Retained Earnings | (22.4M) | (385.7M) | (601.9M) | (752.9M) | (988.7M) | (939.3M) | |
Other Current Assets | 3.9M | 16.9M | 17.4M | 19.4M | 54.2M | 56.9M | |
Total Liab | 34.1M | 138.1M | 108.1M | 124.0M | 175.3M | 107.4M | |
Total Current Assets | 11.2M | 595.1M | 393.6M | 315.1M | 536.4M | 342.9M |
Centessa Pharmaceuticals Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 378K | 2.5M | 7.0M | 9.9M | (10.1M) | (9.6M) | |
Operating Income | (10.4M) | (139.3M) | (212.3M) | (171.3M) | (201.1M) | (191.0M) | |
Ebit | (10.4M) | (379.2M) | (212.4M) | (166.9M) | (150.2M) | (157.7M) | |
Research Development | 9.3M | 96.3M | 155.1M | 124.4M | 150.2M | 98.9M | |
Ebitda | (10.4M) | (379.2M) | (212.3M) | (166.1M) | (201.1M) | (211.1M) | |
Income Before Tax | (10.7M) | (381.7M) | (217.0M) | (176.1M) | (232.9M) | (244.6M) | |
Net Income | (11.0M) | (381.9M) | (216.2M) | (151.1M) | (235.8M) | (247.5M) | |
Income Tax Expense | 378K | 114.0K | (747K) | (25.1M) | 2.8M | 3.0M |
Centessa Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Centessa Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Centessa Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Centessa Pharmaceuticals competition to find correlations between indicators driving Centessa Pharmaceuticals's intrinsic value. More Info.Centessa Pharmaceuticals PLC is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Centessa Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Centessa Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Centessa Pharmaceuticals Systematic Risk
Centessa Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Centessa Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Centessa Pharmaceuticals correlated with the market. If Beta is less than 0 Centessa Pharmaceuticals generally moves in the opposite direction as compared to the market. If Centessa Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Centessa Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Centessa Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Centessa Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Centessa Pharmaceuticals Thematic Clasifications
Centessa Pharmaceuticals PLC is part of several thematic ideas from Computers to Biotech. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Centessa Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Centessa Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Centessa Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Centessa Pharmaceuticals March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Centessa Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Centessa Pharmaceuticals PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Centessa Pharmaceuticals PLC based on widely used predictive technical indicators. In general, we focus on analyzing Centessa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Centessa Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio | (0.03) | |||
Maximum Drawdown | 15.09 | |||
Value At Risk | (5.83) | |||
Potential Upside | 6.3 |
Complementary Tools for Centessa Stock analysis
When running Centessa Pharmaceuticals' price analysis, check to measure Centessa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Centessa Pharmaceuticals is operating at the current time. Most of Centessa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Centessa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Centessa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Centessa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |